SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72865
Title:
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.
Authors:
Clamp, Andrew R; Mäenpää, J; Cruickshank, D; Ledermann, J A; Wilkinson, Peter M; Welch, Richard; Chan, S; Vasey, Paul; Sorbe, B; Hindley, A; Jayson, Gordon C ( 0000-0002-8515-8944 )
Abstract:
The feasibility of combination irinotecan, carboplatin and docetaxel chemotherapy as first-line treatment for advanced epithelial ovarian carcinoma was assessed. One hundred patients were randomised to receive four 3-weekly cycles of carboplatin (area under the curve (AUC) 7) followed by four 3-weekly cycles of docetaxel 100 mg m(-2) (arm A, n=51) or docetaxel 60 mg m(-2) with irinotecan 200 mg m(-2) (arm B, n=49). Neither arm met the formal feasibility criterion of an eight-cycle treatment completion rate that was statistically greater than 60% (arm A 71% (90% confidence interval (CI) 58-81%; P=0.079; arm B 67% (90% CI 55-78%; P=0.184)). Median-dose intensities were >85% of planned dose for all agents. In arms A and B, 15.6 and 12.2% of patients, respectively, withdrew owing to treatment-related toxicity. Grade 3-4 sensory neurotoxicity was more common in arm A (1.9 vs 0%) and grade 3-4 diarrhoea was more common in arm B (0.6 vs 3.5%). Of patients with radiologically evaluable disease at baseline, 50 and 48% responded to therapy in arms A and B, respectively; at median 17.1 months' follow-up, median progression-free survival was 17.1 and 15.9 months, respectively. Although both arms just failed to meet the formal statistical feasibility criteria, the observed completion rates of around 70% were reasonable. The addition of irinotecan to first-line carboplatin and docetaxel chemotherapy was generally well tolerated although associated with increased gastrointestinal toxicity. Further exploratory studies of topoisomerase-I inhibitors in this setting may be warranted.
Affiliation:
Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, UK.
Citation:
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. 2006, 94 (1):55-61 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
16-Jan-2006
URI:
http://hdl.handle.net/10541/72865
DOI:
10.1038/sj.bjc.6602910
PubMed ID:
16404360
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorClamp, Andrew R-
dc.contributor.authorMäenpää, J-
dc.contributor.authorCruickshank, D-
dc.contributor.authorLedermann, J A-
dc.contributor.authorWilkinson, Peter M-
dc.contributor.authorWelch, Richard-
dc.contributor.authorChan, S-
dc.contributor.authorVasey, Paul-
dc.contributor.authorSorbe, B-
dc.contributor.authorHindley, A-
dc.contributor.authorJayson, Gordon C-
dc.date.accessioned2009-07-07T15:49:01Z-
dc.date.available2009-07-07T15:49:01Z-
dc.date.issued2006-01-16-
dc.identifier.citationSCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. 2006, 94 (1):55-61 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid16404360-
dc.identifier.doi10.1038/sj.bjc.6602910-
dc.identifier.urihttp://hdl.handle.net/10541/72865-
dc.description.abstractThe feasibility of combination irinotecan, carboplatin and docetaxel chemotherapy as first-line treatment for advanced epithelial ovarian carcinoma was assessed. One hundred patients were randomised to receive four 3-weekly cycles of carboplatin (area under the curve (AUC) 7) followed by four 3-weekly cycles of docetaxel 100 mg m(-2) (arm A, n=51) or docetaxel 60 mg m(-2) with irinotecan 200 mg m(-2) (arm B, n=49). Neither arm met the formal feasibility criterion of an eight-cycle treatment completion rate that was statistically greater than 60% (arm A 71% (90% confidence interval (CI) 58-81%; P=0.079; arm B 67% (90% CI 55-78%; P=0.184)). Median-dose intensities were >85% of planned dose for all agents. In arms A and B, 15.6 and 12.2% of patients, respectively, withdrew owing to treatment-related toxicity. Grade 3-4 sensory neurotoxicity was more common in arm A (1.9 vs 0%) and grade 3-4 diarrhoea was more common in arm B (0.6 vs 3.5%). Of patients with radiologically evaluable disease at baseline, 50 and 48% responded to therapy in arms A and B, respectively; at median 17.1 months' follow-up, median progression-free survival was 17.1 and 15.9 months, respectively. Although both arms just failed to meet the formal statistical feasibility criteria, the observed completion rates of around 70% were reasonable. The addition of irinotecan to first-line carboplatin and docetaxel chemotherapy was generally well tolerated although associated with increased gastrointestinal toxicity. Further exploratory studies of topoisomerase-I inhibitors in this setting may be warranted.en
dc.language.isoenen
dc.subjectFallopian Tube Canceren
dc.subjectOvarian Canceren
dc.subjectPeritoneal Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshArea Under Curve-
dc.subject.meshCamptothecin-
dc.subject.meshCarboplatin-
dc.subject.meshCarcinoma-
dc.subject.meshDisease Progression-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshFallopian Tube Neoplasms-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInfusions, Intravenous-
dc.subject.meshMiddle Aged-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshPeritoneal Neoplasms-
dc.subject.meshSurvival Analysis-
dc.subject.meshTaxoids-
dc.subject.meshTreatment Outcome-
dc.titleSCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.